<DOC>
	<DOC>NCT01013376</DOC>
	<brief_summary>The safety and comfort of repeated administrations of a topically-administered ophthalmic formulation of MC-1101 will be established through investigator assessments and subject reporting over a 3 day period. Safety assessments will be performed on both normal, healthy subjects as well as those with the signs and symptoms of early non-exudative age-related macular degeneration (dry AMD).</brief_summary>
	<brief_title>A Pilot Study of the Safety of MC-1101 in Both Normal Volunteers and Patients With Early Dry AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Clinical diagnosis of dry AMD or; Normal, healthy volunteer Uncontrolled systemic disease Women who are pregnant, nursing, or planning a pregnancy during the study's duration</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>